Filing Details

Accession Number:
0001209191-18-005827
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-29 16:14:57
Reporting Period:
2018-01-25
Accepted Time:
2018-01-29 16:14:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1566044 Menlo Therapeutics Inc. MNLO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1397906 Albert Cha 204 Cardinal Way, 2Nd Floor
Redwood City CA 94063
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-25 258,432 $17.00 258,432 No 4 P Indirect By Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2018-01-25 35,686 $17.00 35,686 No 4 P Indirect By Vivo Capital Surplus Fund III, L.P.
Common Stock Acquisiton 2018-01-29 2,348,550 $0.00 2,606,982 No 4 C Indirect By Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2018-01-29 324,306 $0.00 359,992 No 4 C Indirect By Vivo Capital Surplus Fund III, L.P.
Common Stock Acquisiton 2018-01-29 917,559 $0.00 3,524,541 No 4 C Indirect By Vivo Capital Fund VIII, L.P.
Common Stock Acquisiton 2018-01-29 126,703 $0.00 486,695 No 4 C Indirect By Vivo Capital Surplus Fund III, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Vivo Capital Fund VIII, L.P.
No 4 P Indirect By Vivo Capital Surplus Fund III, L.P.
No 4 C Indirect By Vivo Capital Fund VIII, L.P.
No 4 C Indirect By Vivo Capital Surplus Fund III, L.P.
No 4 C Indirect By Vivo Capital Fund VIII, L.P.
No 4 C Indirect By Vivo Capital Surplus Fund III, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2018-01-29 6,335,215 $0.00 2,348,550 $0.00
Common Stock Series B Preferred Stock Disposition 2018-01-29 874,817 $0.00 324,306 $0.00
Common Stock Series C Preferred Stock Disposition 2018-01-29 2,475,118 $0.00 917,559 $0.00
Common Stock Series C Preferred Stock Disposition 2018-01-29 341,784 $0.00 126,703 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The reporting person is one of the managing members of Vivo Capital VII, LLC ("Vivo LLC"), which is the general partner of each of Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), the record holders of the securities, and the reporting person therefore may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  2. Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.